History

The discovery of clinically applicable gene signatures from cancer cells in AML patients led to the founding of Skyline Diagnostics in 2005. The investigators and clinicians of the Departments of Hematology and Bioinformatics of the Erasmus Medical Center, among whom Chief Scientific Officer professor Bob Löwenberg, teamed up with biotech entrepreneur Chief Executive Officer Henk Viëtor, PhD to develop that discovery into a powerful clinical tool: the AMLprofiler.
Since its inception, the company has perfected and launched its first product, the AMLprofiler and filled its pipeline with other, promising new Profilers. Making use of the GeneChip® Technology as an official Powered-by-Affymetrix partner, Skyline takes microarray technology to a whole new level by helping clinicians fight cancer better. In the recent years, we expanded to become a company of over 20 ambitious people motivated to make personalized medicine a reality in oncology.